banner add

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

from NYT > Health https://ift.tt/NWShtOr
via IFTTT

No comments

UnitedHealth Group Reports Flat First-Quarter Earnings

One of the nation’s largest insurers, the company’s profits were higher than analysts’ expectations but still fell short of showing a signif...

Theme images by PLAINVIEW. Powered by Blogger.